Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 19/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118136 | 0.87 | FFAR1 (0.50) | FFAR1MRGPRX4PPARD | |
| SCHEMBL13548835 | 0.87 | FFAR1 (0.55) | FFAR1MRGPRX4PPARD | |
| SCHEMBL3525795 | 0.81 | FFAR1 (0.88) | FFAR1MRGPRX4PPARD | |
| SCHEMBL13118134 | 0.81 | FFAR1 (0.52) | FFAR1MRGPRX4PPARD | |
| SCHEMBL13550323 | 0.80 | FFAR1 (0.79) | FFAR1MRGPRX4PPARD | |
| SCHEMBL13550339 | 0.79 | FFAR1 (0.74) | FFAR1MRGPRX4PPARD | |
| SCHEMBL13140189 | 0.78 | FFAR1 (0.79) | FFAR1MRGPRX4AKR1B1FFAR4 | |
| SCHEMBL13118336 | 0.78 | FFAR1 (0.76) | FFAR1MRGPRX4PPARD | |
| SCHEMBL3555589 | 0.78 | FFAR1 (0.72) | FFAR1MRGPRX4PPARD | |
| SCHEMBL6104254 | 0.78 | FFAR1 (0.72) | FFAR1MRGPRX4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | FFAR1 1245/4885MRGPRX4 713/4885PPARD 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.